JNK2 ablation or CaMKII inhibition eliminated aberrant intracellular Ca2+ waves and enhanced atrial fibrillation propensity driven by JNK2-CaMKII crosstalk in aged atria.
Does JNK2 ablation or CaMKII inhibition prevent atrial arrhythmogenesis in aged atria?
JNK2-driven CaMKII activation is a causal factor in atrial arrhythmic remodeling in aging, identifying JNK2 as a potential therapeutic target for atrial fibrillation.
Rationale: Atrial fibrillation (AF) is the most common arrhythmia, and advanced age is an inevitable and predominant AF risk factor. However, the mechanisms that couple aging and AF propensity remain unclear, making targeted therapeutic interventions unattainable. Objective: To explore the functional role of an important stress response JNK (c-Jun N-terminal kinase) in sarcoplasmic reticulum Ca 2+ handling and consequently Ca 2+ -mediated atrial arrhythmias. Methods and Results: We used a series of cutting-edge electrophysiological and molecular techniques, exploited the power of transgenic mouse models to detail the molecular mechanism, and verified its clinical applicability in parallel studies on donor human hearts. We discovered that significantly increased activity of the stress response kinase JNK2 (JNK isoform 2) in the aged atria is involved in arrhythmic remodeling. The JNK-driven atrial proarrhythmic mechanism is supported by a pathway linking JNK, CaMKII (Ca 2+ /calmodulin-dependent kinase II), and sarcoplasmic reticulum Ca 2+ release RyR2 (ryanodine receptor) channels. JNK2 activates CaMKII, a critical proarrhythmic molecule in cardiac muscle. In turn, activated CaMKII upregulates diastolic sarcoplasmic reticulum Ca 2+ leak mediated by RyR2 channels. This leads to aberrant intracellular Ca 2+ waves and enhanced AF propensity. In contrast, this mechanism is absent in young atria. In JNK challenged animal models, this is eliminated by JNK2 ablation or CaMKII inhibition. Conclusions: We have identified JNK2-driven CaMKII activation as a novel mode of kinase crosstalk and a causal factor in atrial arrhythmic remodeling, making JNK2 a compelling new therapeutic target for AF prevention and treatment.
Yan et al. (Fri,) conducted a other in Atrial fibrillation. JNK2 ablation or CaMKII inhibition vs. Untreated aged atria was evaluated on Atrial arrhythmic remodeling and aberrant intracellular Ca2+ waves. JNK2 ablation or CaMKII inhibition eliminated aberrant intracellular Ca2+ waves and enhanced atrial fibrillation propensity driven by JNK2-CaMKII crosstalk in aged atria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: